drugset / Trial / NCT04434131

Treatment With Investigational Convalescent Plasma and Measure Antibody Levels in Patients Hospitalized With COVID-19

NCT04434131

Phase 2 Completed 12 enrolled University of New Mexico
NaSingle-groupOpen-labelPrevention

Summary

This is an open label pilot study designed to provide access to treatment with investigational convalescent plasma and assess the relationship between NAb titers in the investigational convalescent plasma compared to changes in NAb levels in the recipient in hospitalized patients with COVID-19.

Timeline

Start
2020-04-28
Primary completion
2020-07-31
Completion
2021-03-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Convalescent Plasma Protein / enzyme biologic 200 ml

Indications